Test in Focus
T-cell lymphoma is a term used to describe a group of cancers derived from T cells, which are cells of the immune system that play a critical role in immune function. T-cell lymphoma is not a single disease, but rather a name given to a wide variety of diseases that have different pathologic and clinical features.
With more than 30 identified subtypes of T-cell lymphoma in existence, making an accurate, definitive diagnosis can be difficult. In addition to an extensive IHC and FISH test offerings, Mayo Clinic’s hematopathology team not only has extensive experience detecting and diagnosing T-cell neoplasms, but also frequently provides T-cell lymphoma consultations for clients around the globe to help give clinicians the diagnostic answers they need to effectively treat T-cell lymphoma patients.
“The most common molecular assays that we do right now are T-cell receptor gene rearrangement studies for clonality,” says clinical hematopathologist Andrew Feldman, M.D. “And that's often used to differentiate between clonal or neoplastic processes and reactive processes.”
Learn more by listening to the below “Test in Focus” episode of our “Answers From the Lab” podcast with Dr. Feldman.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay measures concentrations of the small dense LDL subtype, to better guide clinical care.
Identifying a precise genetic cause of hearing loss impacts clinical management. Nicole Boczek, Ph.D., and Melanie Meyer, M.S., CGC, explain how Mayo Clinic Laboratories' updated panel yields comprehensive results for optimal patient care.
In this test-specific episode of the "Answers From the Lab" podcast, Wei Shen, Ph.D., explains how Mayo Clinic Laboratories' new breast cancer panel provides rapid results to guide critical decisions about treatment and screening.